Delayed Symptoms in Patients Recovered from COVID-19

Abstract

Background: COVID-19 is a new disease, so we don’t know what comes next. Since information on delayed symptoms is limited, this study was conducted to assess the frequency of delayed symptoms in patients with COVID-19.
 Methods: This follow-up cross-sectional study was conducted in a referral general hospital in Tehran, Iran from Feb to Apr 2020. Two hundred patients hospitalized for COVID-19 and were discharged were assessed for delayed symptoms 6 wk after discharge.
 Results: The mean age of the participants was 55.58±13.52, and 160 (80%) Of them were male. On admission to hospital, patients reported a mean of 5.63±2.88 symptoms per patient, range from 1 to 14 symptoms. Dyspnea was seen in 119 (59.5%) 0f them as the most frequent symptom. Then weakness, myalgia, and shivering were reported with a frequency of 111 (55.5%), 107 (53.5%), and 103 (51.5%), respectively. Six weeks after discharge reassessment was done. None of the patients was readmitted to the hospital. Ninety-four (42%) of them were symptom-free. Fatigue was the most frequent delayed symptom with a frequency of 39 (19.5%), and then dyspnea, weakness, and activity intolerance with a frequency of 37 (18.5%), 36 (18%), and 29 (14.5%) were reported, respectively.
 Conclusion: Fatigue, dyspnea, weakness, anxiety, and activity intolerance were most frequent delayed symptoms, respectively. Majority of patient was symptoms free and those with symptom, had mild to moderate symptoms. The importance of symptoms is not fully recognized. Follow up clinics and in some cases rehabilitation programs may be helpful

Follow‐up of renal transplant recipients after acute COVID‐19—A prospective cohort single‐center study

“… 4 Moradian et al reported that 42% of their patients were symptom‐free, while fatigue persisted in 19.5%, followed by dyspnea (18.5%), weakness (18%), and activity intolerance (14.5%). 8 …”

“…In the study of Huang et al, which included 1733 discharged patients with COVID‐19, the most common symptoms were fatigue or muscle weakness (63%) and sleep difficulties (26%) 4 . Moradian et al reported that 42% of their patients were symptom‐free, while fatigue persisted in 19.5%, followed by dyspnea (18.5%), weakness (18%), and activity intolerance (14.5%) 8 …”

“…Interestingly, some patients with severe COVID‐19 recover within a short period, while some with mild forms of the disease, or even asymptomatic, develop significant post‐COVID‐19 complications and require a long time for recovery 6 . A few studies focused on post‐COVID‐19 in the general population 1–8 …”

COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review

“…84 However symptom duration, patient populations, and length of follow-up are highly variable between studies, with reported rates of full recovery between 13% and 86% at follow-up ranging from 30 to 186 days (Table 2). 71–73,75,78,83,85–103…”

Revised meta-analysis and pooled estimate of audio-vestibular symptoms associated with COVID-19

“…Ozçelik Korkmaz et al (2021) [d] Salahuddin et al (2020) [e] Salepci et al (2021) [f] Savtale et al (2021) [g] Carfi et al (2020) [h] Davis (2020) [i] Elibol (2021) [j] Membrilla et al (2020) [k] Rocha-Filho & Magalhaes (2020) [l] Stavem et al (2020) [m] Micarelli et al (2020) [n] Dror et al (2021) [o] Go€ ertz et al (2020) [p] Lechien et al (2020) [q] Daikhes et al (2020) [r] Freni et al (2020) [s] Iltaf et al (2020) [t] Karimi et al (2020) [u] Khalaf, M. (2020) [v] Klopfenstein et al (2020) [w] Mustafa (2020) [x] Moradian et al (2020) [y] Cirulli (2020) [z] Kamal et al (2021) [ Ð ] Munro et al (2020) [ §] Viola et al (2020). where there was uncertainty or missing data.…”